A Phase 3 interventional study of 13vPnC in Healthy, sponsored by Pfizer. Completed at 2 sites in Japan. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-11-11.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate (13vPnC) vaccine in healthy Japanese adults aged >= 50 years.
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stratum 1: \>= 65 years of age
Biological: 13vPnC
Stratum 2: 50 to 64 years of age
Biological: 13vPnC
13vPnC for both stratum
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Overall Population
Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% confidence intervals (CIs) on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: 1 month after vaccination
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: 1 month after vaccination
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Overall Population
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: Prevaccination (Day 1), 1 month after vaccination
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes From Prevaccination to 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: Prevaccination (Day 1), 1 month after vaccination
Comparison of Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) for the 13 Serotypes 1 Month After Vaccination by Age Group
Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: 1 month after vaccination
Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Overall Population
For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Comparison of Percentage of Participants Achieving Serotype Specific OPA Titers ≥ Lower Limit of Quantitation (LLOQ) for the 13 Serotypes 1 Month After Vaccination by Age Group
For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population
For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Comparison of Percentage of Participants Achieving ≥2-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group
For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Overall Population
For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Comparison of Percentage of Participants Achieving ≥4-fold Rise in Serotype Specific OPA Titers for the 13 Serotypes 1 Month After Vaccination by Age Group
For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
Time frame: 1 month after vaccination
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Overall Population
Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: 1 month after vaccination
Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: 1 month after vaccination
Comparison of Pneumococcal Immunoglobulin G (IgG) Geometric Mean Concentrations (GMCs) for the 13 Serotypes 1 Month After Vaccination by Age Group
Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
Time frame: 1 month after vaccination
Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Overall Population
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: 1 month after vaccination
Immunoglobulin G (IgG) Geometric Mean Fold Rises (GMFRs) for the 13 Serotypes 1 Month After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
Time frame: 1 month after vaccination
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Overall Population
Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).
Time frame: Day 1 through 14
Percentage of Participants Reporting Pre-specified Local Reactions Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).
Time frame: Day 1 through 14
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Overall Population
Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.
Time frame: Day 1 through 14
Percentage of Participants Reporting Pre-specified Systemic Events Within 14 Days After Vaccination for Age Groups 50 to 64 Years and ≥65 Years
Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.
Time frame: Day 1 through 14
| Milestone | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Started | 134 | 137 |
| Received study treatment | 134 | 136 |
| Evaluable immunogenicity population | 134 | 134 |
| Completed | 134 | 135 |
| Not completed | 0 | 2 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% confidence intervals (CIs) on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| titer | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 124 (101.5 to 150.7) |
| Serotype 3 | 62 (53.1 to 73.4) |
| Serotype 4 | 1333 (1054.4 to 1684.2) |
| Serotype 5 | 215 (172.0 to 269.2) |
| Serotype 6A | 2256 (1884.4 to 2700.3) |
| Serotype 6B | 2861 (2406.4 to 3401.1) |
| Serotype 7F | 1793 (1476.1 to 2177.7) |
| Serotype 9V | 863 (652.9 to 1141.5) |
| Serotype 14 | 1494 (1267.1 to 1761.9) |
| Serotype 18C | 2082 (1683.5 to 2575.0) |
| Serotype 19A | 874 (729.0 to 1047.8) |
| Serotype 19F | 821 (655.7 to 1027.8) |
| Serotype 23F | 538 (415.9 to 696.7) |
Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| titer | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 93 (70.3 to 124.2) | 162 (124.0 to 212.6) |
| Serotype 3 | 53 (42.0 to 67.8) | 73 (58.6 to 90.9) |
| Serotype 4 | 1209 (830.1 to 1762.2) | 1464 (1098.8 to 1950.9) |
| Serotype 5 | 159 (113.6 to 221.2) | 289 (214.7 to 387.9) |
| Serotype 6A | 1667 (1283.1 to 2165.9) | 3082 (2431.0 to 3908.2) |
| Serotype 6B | 2556 (1967.1 to 3320.8) | 3182 (2527.6 to 4004.7) |
| Serotype 7F | 1469 (1075.6 to 2005.6) | 2218 (1772.6 to 2776.3) |
| Serotype 9V | 738 (497.8 to 1094.8) | 1007 (675.2 to 1501.7) |
| Serotype 14 | 1294 (1027.3 to 1629.2) | 1726 (1362.8 to 2185.2) |
| Serotype 18C | 1503 (1087.0 to 2078.8) | 2862 (2187.0 to 3745.6) |
| Serotype 19A | 616 (488.1 to 776.7) | 1241 (949.3 to 1621.7) |
| Serotype 19F | 614 (438.9 to 858.0) | 1083 (804.7 to 1458.5) |
| Serotype 23F | 361 (243.9 to 533.2) | 788 (566.6 to 1097.2) |
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 23.3 (19.17 to 28.31) |
| Serotype 3 | 11.5 (9.69 to 13.67) |
| Serotype 4 | 79.6 (55.79 to 113.47) |
| Serotype 5 | 42.4 (33.64 to 53.51) |
| Serotype 6A | 48.8 (35.04 to 67.87) |
| Serotype 6B | 16.6 (11.79 to 23.51) |
| Serotype 7F | 137.2 (99.26 to 189.69) |
| Serotype 9V | 13.4 (9.17 to 19.46) |
| Serotype 14 | 12.4 (9.23 to 16.76) |
| Serotype 18C | 52.9 (38.41 to 72.82) |
| Serotype 19A | 41.9 (32.46 to 54.22) |
| Serotype 19F | 42.7 (32.34 to 56.25) |
| Serotype 23F | 47.5 (35.23 to 63.92) |
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 18.7 (14.02 to 24.91) | 28.8 (22.17 to 37.52) |
| Serotype 3 | 9.8 (7.62 to 12.49) | 13.6 (10.66 to 17.24) |
| Serotype 4 | 50.7 (29.40 to 87.32) | 123.3 (78.54 to 193.67) |
| Serotype 5 | 34.3 (24.61 to 47.90) | 52.0 (37.59 to 71.88) |
| Serotype 6A | 32.3 (20.50 to 50.81) | 74.7 (46.39 to 120.22) |
| Serotype 6B | 11.2 (6.98 to 18.09) | 24.1 (14.68 to 39.60) |
| Serotype 7F | 99.9 (62.24 to 160.40) | 192.5 (124.26 to 298.35) |
| Serotype 9V | 7.3 (4.42 to 12.02) | 24.2 (14.02 to 41.86) |
| Serotype 14 | 10.6 (7.00 to 16.08) | 14.6 (9.46 to 22.44) |
| Serotype 18C | 31.0 (19.68 to 48.75) | 89.2 (57.54 to 138.25) |
| Serotype 19A | 25.3 (18.75 to 34.13) | 69.5 (46.56 to 103.89) |
| Serotype 19F | 25.3 (17.42 to 36.65) | 70.3 (47.39 to 104.14) |
| Serotype 23F | 40.8 (26.53 to 62.89) | 54.7 (36.11 to 82.94) |
Serotype-specific antibody-mediated opsonophagocytic activity (functional antibodies) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) as measured by a quantitative opsonophagocytic activity assay (OPA). OPA titers will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean titers (GMTs). The 2-sided, 95% CIs on the GMTs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| titer | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 93 (70.3 to 124.2) | 164 (125.1 to 213.9) |
| Serotype 3 | 54 (42.2 to 67.9) | 73 (58.6 to 90.2) |
| Serotype 4 | 1331 (967.6 to 1831.7) | 1786 (1390.9 to 2293.9) |
| Serotype 5 | 171 (123.9 to 236.4) | 294 (219.9 to 393.0) |
| Serotype 6A | 1663 (1287.0 to 2147.9) | 3148 (2502.2 to 3960.6) |
| Serotype 6B | 2462 (1905.0 to 3181.7) | 3383 (2721.3 to 4204.8) |
| Serotype 7F | 1484 (1097.7 to 2005.3) | 2247 (1818.6 to 2776.7) |
| Serotype 9V | 797 (557.1 to 1138.9) | 1062 (735.5 to 1533.7) |
| Serotype 14 | 1289 (1033.8 to 1608.1) | 1740 (1386.0 to 2183.8) |
| Serotype 18C | 1530 (1114.5 to 2099.8) | 2922 (2243.8 to 3804.0) |
| Serotype 19A | 604 (483.8 to 754.4) | 1267 (979.8 to 1637.9) |
| Serotype 19F | 627 (454.7 to 863.7) | 1094 (814.1 to 1470.4) |
| Serotype 23F | 398 (276.1 to 575.1) | 824 (596.3 to 1137.5) |
For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 91.6 (87.6 to 94.7) |
| Serotype 3 | 89.8 (85.6 to 93.2) |
| Serotype 4 | 95.2 (91.8 to 97.5) |
| Serotype 5 | 88.6 (84.0 to 92.2) |
| Serotype 6A | 98.5 (96.2 to 99.6) |
| Serotype 6B | 98.5 (96.2 to 99.6) |
| Serotype 7F | 96.5 (93.5 to 98.4) |
| Serotype 9V | 89.1 (84.7 to 92.5) |
| Serotype 14 | 98.5 (96.2 to 99.6) |
| Serotype 18C | 96.6 (93.7 to 98.4) |
| Serotype 19A | 98.9 (96.7 to 99.8) |
| Serotype 19F | 94.2 (90.6 to 96.7) |
| Serotype 23F | 89.2 (84.8 to 92.7) |
For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 89.1 (82.5 to 93.9) | 94.0 (88.6 to 97.4) |
| Serotype 3 | 87.9 (81.1 to 92.9) | 91.8 (85.8 to 95.8) |
| Serotype 4 | 93.5 (87.6 to 97.2) | 96.9 (92.3 to 99.1) |
| Serotype 5 | 85.8 (78.5 to 91.4) | 91.3 (85.0 to 95.6) |
| Serotype 6A | 97.7 (93.5 to 99.5) | 99.2 (95.9 to 100.0) |
| Serotype 6B | 97.7 (93.4 to 99.5) | 99.3 (95.9 to 100.0) |
| Serotype 7F | 93.9 (88.4 to 97.3) | 99.2 (95.7 to 100.0) |
| Serotype 9V | 88.6 (82.0 to 93.5) | 89.5 (83.0 to 94.1) |
| Serotype 14 | 98.5 (94.6 to 99.8) | 98.5 (94.6 to 99.8) |
| Serotype 18C | 95.5 (90.4 to 98.3) | 97.7 (93.5 to 99.5) |
| Serotype 19A | 99.2 (95.8 to 100.0) | 98.5 (94.6 to 99.8) |
| Serotype 19F | 93.0 (87.1 to 96.7) | 95.3 (90.2 to 98.3) |
| Serotype 23F | 86.2 (79.0 to 91.6) | 92.3 (86.3 to 96.2) |
For OPA assays serotype-specific lower limit of quantitation (LLOQ) was derived the 13 serotypes: serotype 1=18; 3=12; 4=21; 5=29; 6A=37; 6B=43; 7F=210; 9V=345; 14=35; 18C=31; 19A=18; 19F=48; 23F=13. For each serotype the proportion (percentage of participants) achieving an OPA titer of at least 1:LLOQ was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 89.1 (82.5 to 93.9) | 94.0 (88.6 to 97.4) |
| Serotype 3 | 87.9 (81.1 to 92.9) | 91.8 (85.8 to 95.8) |
| Serotype 4 | 93.5 (87.6 to 97.2) | 96.9 (92.3 to 99.1) |
| Serotype 5 | 85.8 (78.5 to 91.4) | 91.3 (85.0 to 95.6) |
| Serotype 6A | 97.7 (93.5 to 99.5) | 99.2 (95.9 to 100.0) |
| Serotype 6B | 97.7 (93.4 to 99.5) | 99.3 (95.9 to 100.0) |
| Serotype 7F | 93.9 (88.4 to 97.3) | 99.2 (95.7 to 100.0) |
| Serotype 9V | 88.6 (82.0 to 93.5) | 89.5 (83.0 to 94.1) |
| Serotype 14 | 98.5 (94.6 to 99.8) | 98.5 (94.6 to 99.8) |
| Serotype 18C | 95.5 (90.4 to 98.3) | 97.7 (93.5 to 99.5) |
| Serotype 19A | 99.2 (95.8 to 100.0) | 98.5 (94.6 to 99.8) |
| Serotype 19F | 93.0 (87.1 to 96.7) | 95.3 (90.2 to 98.3) |
| Serotype 23F | 86.2 (79.0 to 91.6) | 92.3 (86.3 to 96.2) |
For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 89.7 (85.4 to 93.1) |
| Serotype 3 | 84.4 (79.5 to 88.6) |
| Serotype 4 | 84.9 (79.2 to 89.5) |
| Serotype 5 | 87.1 (82.2 to 91.1) |
| Serotype 6A | 84.5 (79.5 to 88.8) |
| Serotype 6B | 68.4 (62.0 to 74.2) |
| Serotype 7F | 86.1 (81.1 to 90.2) |
| Serotype 9V | 61.3 (54.8 to 67.6) |
| Serotype 14 | 67.2 (61.0 to 73.0) |
| Serotype 18C | 85.6 (80.7 to 89.7) |
| Serotype 19A | 92.3 (88.3 to 95.3) |
| Serotype 19F | 88.0 (83.3 to 91.8) |
| Serotype 23F | 81.3 (75.9 to 86.0) |
For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 86.0 (78.8 to 91.5) | 93.2 (87.5 to 96.9) |
| Serotype 3 | 81.7 (74.0 to 87.9) | 87.1 (80.2 to 92.3) |
| Serotype 4 | 79.2 (70.0 to 86.6) | 90.4 (83.0 to 95.3) |
| Serotype 5 | 84.7 (77.0 to 90.7) | 89.4 (82.6 to 94.3) |
| Serotype 6A | 82.0 (74.3 to 88.3) | 87.1 (79.9 to 92.4) |
| Serotype 6B | 61.7 (52.2 to 70.6) | 74.6 (65.9 to 82.0) |
| Serotype 7F | 82.5 (74.8 to 88.7) | 89.8 (82.9 to 94.6) |
| Serotype 9V | 52.5 (43.1 to 61.8) | 70.0 (61.0 to 78.0) |
| Serotype 14 | 62.4 (53.3 to 70.9) | 72.0 (63.3 to 79.7) |
| Serotype 18C | 80.3 (72.3 to 86.8) | 90.8 (84.4 to 95.1) |
| Serotype 19A | 92.7 (86.7 to 96.6) | 91.9 (85.7 to 96.1) |
| Serotype 19F | 86.1 (78.6 to 91.7) | 89.8 (83.3 to 94.5) |
| Serotype 23F | 80.0 (71.7 to 86.7) | 82.5 (74.8 to 88.7) |
For each serotype the proportion (percentage of participants) achieving at least a 2-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 86.0 (78.8 to 91.5) | 93.2 (87.5 to 96.9) |
| Serotype 3 | 81.7 (74.0 to 87.9) | 87.1 (80.2 to 92.3) |
| Serotype 4 | 79.2 (70.0 to 86.6) | 90.4 (83.0 to 95.3) |
| Serotype 5 | 84.7 (77.0 to 90.7) | 89.4 (82.6 to 94.3) |
| Serotype 6A | 82.0 (74.3 to 88.3) | 87.1 (79.9 to 92.4) |
| Serotype 6B | 61.7 (52.2 to 70.6) | 74.6 (65.9 to 82.0) |
| Serotype 7F | 82.5 (74.8 to 88.7) | 89.8 (82.9 to 94.6) |
| Serotype 9V | 52.5 (43.1 to 61.8) | 70.0 (61.0 to 78.0) |
| Serotype 14 | 62.4 (53.3 to 70.9) | 72.0 (63.3 to 79.7) |
| Serotype 18C | 80.3 (72.3 to 86.8) | 90.8 (84.4 to 95.1) |
| Serotype 19A | 92.7 (86.7 to 96.6) | 91.9 (85.7 to 96.1) |
| Serotype 19F | 86.1 (78.6 to 91.7) | 89.8 (83.3 to 94.5) |
| Serotype 23F | 80.0 (71.7 to 86.7) | 82.5 (74.8 to 88.7) |
For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 88.9 (84.5 to 92.5) |
| Serotype 3 | 76.0 (70.4 to 81.1) |
| Serotype 4 | 74.6 (68.1 to 80.4) |
| Serotype 5 | 85.1 (79.9 to 89.3) |
| Serotype 6A | 75.4 (69.6 to 80.6) |
| Serotype 6B | 57.0 (50.4 to 63.4) |
| Serotype 7F | 81.6 (76.1 to 86.2) |
| Serotype 9V | 50.0 (43.5 to 56.5) |
| Serotype 14 | 56.0 (49.6 to 62.2) |
| Serotype 18C | 77.0 (71.4 to 82.0) |
| Serotype 19A | 85.9 (80.9 to 90.0) |
| Serotype 19F | 78.8 (73.2 to 83.7) |
| Serotype 23F | 75.6 (69.7 to 80.8) |
For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 86.0 (78.8 to 91.5) | 91.7 (85.7 to 95.8) |
| Serotype 3 | 73.3 (64.8 to 80.6) | 78.8 (70.8 to 85.4) |
| Serotype 4 | 65.3 (55.2 to 74.5) | 83.7 (75.1 to 90.2) |
| Serotype 5 | 83.9 (76.0 to 90.0) | 86.2 (78.8 to 91.7) |
| Serotype 6A | 69.5 (60.8 to 77.4) | 81.5 (73.5 to 87.9) |
| Serotype 6B | 51.3 (41.8 to 60.7) | 62.3 (53.1 to 70.9) |
| Serotype 7F | 77.0 (68.6 to 84.0) | 86.4 (78.9 to 92.0) |
| Serotype 9V | 36.4 (27.8 to 45.8) | 63.3 (54.1 to 71.9) |
| Serotype 14 | 52.8 (43.7 to 61.8) | 59.2 (50.1 to 67.9) |
| Serotype 18C | 70.9 (62.1 to 78.6) | 83.1 (75.5 to 89.1) |
| Serotype 19A | 85.5 (78.0 to 91.2) | 86.3 (79.0 to 91.8) |
| Serotype 19F | 73.0 (64.2 to 80.6) | 84.4 (76.9 to 90.2) |
| Serotype 23F | 71.7 (62.7 to 79.5) | 79.4 (71.2 to 86.1) |
For each serotype the proportion (percentage of participants) achieving at least a 4-fold rise on the serotype-specific antibody titer from prevaccination to 1 month postvaccination was computed along with exact, 2-sided 95% confidence interval for the proportion.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 86.0 (78.8 to 91.5) | 91.7 (85.7 to 95.8) |
| Serotype 3 | 73.3 (64.8 to 80.6) | 78.8 (70.8 to 85.4) |
| Serotype 4 | 65.3 (55.2 to 74.5) | 83.7 (75.1 to 90.2) |
| Serotype 5 | 83.9 (76.0 to 90.0) | 86.2 (78.8 to 91.7) |
| Serotype 6A | 69.5 (60.8 to 77.4) | 81.5 (73.5 to 87.9) |
| Serotype 6B | 51.3 (41.8 to 60.7) | 62.3 (53.1 to 70.9) |
| Serotype 7F | 77.0 (68.6 to 84.0) | 86.4 (78.9 to 92.0) |
| Serotype 9V | 36.4 (27.8 to 45.8) | 63.3 (54.1 to 71.9) |
| Serotype 14 | 52.8 (43.7 to 61.8) | 59.2 (50.1 to 67.9) |
| Serotype 18C | 70.9 (62.1 to 78.6) | 83.1 (75.5 to 89.1) |
| Serotype 19A | 85.5 (78.0 to 91.2) | 86.3 (79.0 to 91.8) |
| Serotype 19F | 73.0 (64.2 to 80.6) | 84.4 (76.9 to 90.2) |
| Serotype 23F | 71.7 (62.7 to 79.5) | 79.4 (71.2 to 86.1) |
Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| mcg/mL | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 6.05 (5.05 to 7.24) |
| Serotype 3 | 1.53 (1.36 to 1.72) |
| Serotype 4 | 4.57 (3.87 to 5.39) |
| Serotype 5 | 8.34 (7.28 to 9.56) |
| Serotype 6A | 7.93 (6.79 to 9.25) |
| Serotype 6B | 8.31 (7.08 to 9.75) |
| Serotype 7F | 10.36 (9.01 to 11.91) |
| Serotype 9V | 9.62 (8.29 to 11.16) |
| Serotype 14 | 19.23 (16.47 to 22.44) |
| Serotype 18C | 13.90 (12.10 to 15.96) |
| Serotype 19A | 19.13 (16.54 to 22.13) |
| Serotype 19F | 7.77 (6.40 to 9.43) |
| Serotype 23F | 12.23 (10.34 to 14.46) |
Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| mcg/mL | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 4.65 (3.65 to 5.91) | 7.95 (6.11 to 10.35) |
| Serotype 3 | 1.38 (1.17 to 1.62) | 1.69 (1.43 to 2.00) |
| Serotype 4 | 3.63 (2.88 to 4.59) | 5.78 (4.58 to 7.28) |
| Serotype 5 | 6.74 (5.62 to 8.09) | 10.32 (8.46 to 12.60) |
| Serotype 6A | 6.72 (5.48 to 8.24) | 9.37 (7.44 to 11.80) |
| Serotype 6B | 6.71 (5.42 to 8.32) | 10.28 (8.12 to 13.00) |
| Serotype 7F | 8.90 (7.34 to 10.80) | 12.10 (9.90 to 14.80) |
| Serotype 9V | 6.55 (5.32 to 8.05) | 14.22 (11.72 to 17.25) |
| Serotype 14 | 16.73 (13.59 to 20.59) | 22.12 (17.59 to 27.83) |
| Serotype 18C | 10.47 (8.62 to 12.70) | 18.53 (15.35 to 22.37) |
| Serotype 19A | 13.51 (11.16 to 16.36) | 27.09 (22.07 to 33.25) |
| Serotype 19F | 4.99 (3.92 to 6.37) | 11.92 (8.98 to 15.82) |
| Serotype 23F | 9.38 (7.35 to 11.98) | 15.93 (12.75 to 19.91) |
Serotype-specific IgG antibody concentrations for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F), as measured by enzyme-linked immunosorbent assay (ELISA). IgG concentrations will be logarithmically transformed for analysis; geometric means calculated and expressed as geometric mean concentration (GMC) in micrograms per mL (mcg/mL). The 2-sided, 95% CIs on the GMCs were constructed by back transformation of the CIs for the mean of the logarithmically transformed assay results computed using the Student t distribution.
| mcg/mL | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 4.65 (3.65 to 5.91) | 7.69 (5.94 to 9.96) |
| Serotype 3 | 1.35 (1.15 to 1.58) | 1.69 (1.43 to 2.00) |
| Serotype 4 | 3.53 (2.80 to 4.45) | 5.35 (4.25 to 6.75) |
| Serotype 5 | 6.74 (5.62 to 8.09) | 10.32 (8.46 to 12.60) |
| Serotype 6A | 6.72 (5.48 to 8.24) | 9.45 (7.51 to 11.89) |
| Serotype 6B | 6.71 (5.42 to 8.32) | 10.28 (8.12 to 13.00) |
| Serotype 7F | 8.90 (7.34 to 10.80) | 12.09 (9.92 to 14.73) |
| Serotype 9V | 6.55 (5.32 to 8.05) | 14.22 (11.72 to 17.25) |
| Serotype 14 | 16.73 (13.59 to 20.59) | 22.13 (17.63 to 27.80) |
| Serotype 18C | 10.47 (8.62 to 12.70) | 18.48 (15.32 to 22.28) |
| Serotype 19A | 13.51 (11.16 to 16.36) | 27.09 (22.07 to 33.25) |
| Serotype 19F | 4.69 (3.72 to 5.91) | 11.21 (8.51 to 14.77) |
| Serotype 23F | 9.38 (7.35 to 11.98) | 15.93 (12.75 to 19.91) |
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Serotype 1 | 11.38 (9.65 to 13.43) |
| Serotype 3 | 2.89 (2.60 to 3.22) |
| Serotype 4 | 15.89 (13.45 to 18.77) |
| Serotype 5 | 4.15 (3.64 to 4.74) |
| Serotype 6A | 4.23 (3.69 to 4.84) |
| Serotype 6B | 4.32 (3.76 to 4.96) |
| Serotype 7F | 11.59 (9.96 to 13.49) |
| Serotype 9V | 8.56 (7.43 to 9.87) |
| Serotype 14 | 6.79 (5.78 to 7.98) |
| Serotype 18C | 12.94 (11.01 to 15.21) |
| Serotype 19A | 7.36 (6.39 to 8.48) |
| Serotype 19F | 6.03 (5.10 to 7.14) |
| Serotype 23F | 7.80 (6.70 to 9.07) |
Geometric mean fold rises (GMFRs) for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from prevaccination to 1 month postvaccination were computed using the logarithmically transformed assay results. CI for the GMFRs are back transformations of a CI based on the Student t distribution for the logarithmically transformed assay results.
| fold rise | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Serotype 1 | 8.86 (7.08 to 11.09) | 14.77 (11.65 to 18.72) |
| Serotype 3 | 2.40 (2.07 to 2.79) | 3.47 (2.98 to 4.05) |
| Serotype 4 | 11.33 (9.06 to 14.19) | 22.44 (17.75 to 28.38) |
| Serotype 5 | 3.23 (2.70 to 3.85) | 5.34 (4.42 to 6.46) |
| Serotype 6A | 3.32 (2.80 to 3.94) | 5.39 (4.38 to 6.64) |
| Serotype 6B | 3.26 (2.72 to 3.92) | 5.71 (4.68 to 6.97) |
| Serotype 7F | 9.10 (7.39 to 11.22) | 14.88 (12.00 to 18.45) |
| Serotype 9V | 5.76 (4.77 to 6.95) | 12.80 (10.56 to 15.51) |
| Serotype 14 | 5.93 (4.78 to 7.35) | 7.80 (6.13 to 9.91) |
| Serotype 18C | 9.92 (7.99 to 12.31) | 16.96 (13.42 to 21.43) |
| Serotype 19A | 5.12 (4.30 to 6.10) | 10.57 (8.60 to 12.99) |
| Serotype 19F | 3.80 (3.07 to 4.71) | 9.43 (7.45 to 11.94) |
| Serotype 23F | 6.26 (5.02 to 7.80) | 9.71 (7.91 to 11.91) |
Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).
| percentage of participants | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Redness: any | 14.4 |
| Redness: mild | 8.7 |
| Redness: moderate | 9.3 |
| Redness: severe | 0.5 |
| Swelling: any | 11.5 |
| Swelling: mild | 7.2 |
| Swelling: moderate | 5.8 |
| Swelling: severe | 0.5 |
| Pain: any | 48.3 |
| Pain: mild | 46.1 |
| Pain: moderate | 9.6 |
| Pain: severe | 0.5 |
| Limitation of arm movement: any | 53.2 |
| Limitation of arm movement: mild | 52.2 |
| Limitation of arm movement: moderate | 4.4 |
| Limitation of arm movement: severe | 1.5 |
Local reactions reported using electronic diary. Redness and swelling scaled as Any (redness or swelling present); Mild (2.5 centimeters \[cm\] to 5.0 cm); Moderate (5.1 to 10.0 cm); Severe (\> 10.0 cm). Pain as Any (pain present); Mild (awareness of symptom, easily tolerated); Moderate (discomfort enough to cause interference with usual activity); Severe (incapacitating, inability to do usual activity). Limitation of arm movement scaled as Any (limitation present); Mild (some limitation); Moderate (unable to move above head, able to move above shoulder); Severe (unable to move above shoulder).
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Redness: any | 7.1 | 20.9 |
| Redness: mild | 7.1 | 10.0 |
| Redness: moderate | 1.0 | 16.7 |
| Redness: severe | 0.0 | 0.9 |
| Swelling: any | 8.1 | 14.7 |
| Swelling: mild | 7.1 | 7.3 |
| Swelling: moderate | 2.0 | 9.3 |
| Swelling: severe | 0.0 | 0.9 |
| Pain: any | 52.2 | 44.3 |
| Pain: mild | 49.6 | 42.6 |
| Pain: moderate | 8.9 | 10.3 |
| Pain: severe | 1.0 | 0.0 |
| Limitation of arm movement: any | 53.0 | 53.4 |
| Limitation of arm movement: mild | 51.8 | 52.5 |
| Limitation of arm movement: moderate | 5.1 | 3.7 |
| Limitation of arm movement: severe | 2.1 | 0.9 |
Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.
| percentage of participants | 13vPnC Overall Population (50 to 64 and ≥65 Years of Age) |
|---|---|
| Fever: any ≥37.5 degrees C | 3.4 |
| Fever: mild ≥37.5 but <38.5 degrees C | 2.9 |
| Fever: moderate ≥38.5 but <39 degrees C | 0.5 |
| Fatigue | 31.2 |
| Headache | 19.9 |
| Chills | 12.7 |
| Rash | 10.7 |
| Vomiting | 2.0 |
| Decreased appetite | 12.6 |
| New muscle pain | 31.8 |
| Any aggravated muscle pain | 10.1 |
| New joint pain | 11.0 |
| Any aggravated joint pain | 6.3 |
Systemic events reported using electronic diary. Fever scaled as Any (≥37.5 degrees Celsius \[C\]); Mild (≥37.5 but \<38.5 degrees C); Moderate (≥38.5 but \<39 degrees C); Severe (≥39 to ≤40 degrees C); Potentially life-threatening (\>40 degrees C). Other systemic events include Fatigue, Headache, Chills, Rash, Vomiting, Decreased appetite, New muscle pain, Any aggravated muscle pain, New joint pain, and Any aggravated joint pain.
| percentage of participants | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Fever any ≥37.5 degrees C | 3.1 | 3.7 |
| Fever: mild ≥37.5 but <38.5 degrees C | 2.0 | 3.7 |
| Fever: moderate ≥38.5 but <39 degrees C | 1.0 | 0.0 |
| Fatigue | 38.8 | 24.1 |
| Headache | 26.0 | 14.4 |
| Chills | 14.9 | 10.8 |
| Rash | 8.2 | 13.1 |
| Vomiting | 3.1 | 0.9 |
| Decreased appetite | 16.2 | 9.3 |
| New muscle pain | 34.3 | 29.5 |
| Any aggravated muscle pain | 11.2 | 9.1 |
| New joint pain | 10.0 | 11.8 |
| Any aggravated joint pain | 7.1 | 5.5 |
Collected over Adverse events reported via the electronic-diary were collected within 14 days of vaccination; all other adverse events were documented from the signing of the informed consent form up to approximately one month after vaccination (up to Day 43). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC (50 to 64 Years of Age) | — | 1/134 (0.7%) | 120/134 (89.6%) |
| 13vPnC (≥65 Years of Age) | — | 1/136 (0.7%) | 118/136 (86.8%) |
| Event | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Subarachnoid haemorrhageNervous system disorders | 1/134 | 0/136 |
| Cardiac failure congestiveCardiac disorders | 0/134 | 1/136 |
| Event | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) |
|---|---|---|
| Limitation of arm movement: anySkin and subcutaneous tissue disorders | 61/115 | 63/118 |
| Limitation of arm movement: mildSkin and subcutaneous tissue disorders | 59/114 | 62/118 |
| Pain: anySkin and subcutaneous tissue disorders | 60/115 | 51/115 |
| Pain: mildSkin and subcutaneous tissue disorders | 56/113 | 49/115 |
| Injection site movement impairmentGeneral disorders | 48/134 | 54/136 |
| Injection site painGeneral disorders | 53/134 | 52/136 |
| FatigueGeneral disorders | 40/103 | 27/112 |
| New muscle painGeneral disorders | 36/105 | 33/112 |
| HeadacheGeneral disorders | 26/100 | 16/111 |
| Redness: anySkin and subcutaneous tissue disorders | 7/98 | 23/110 |
| Age Continuous(years) | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) | Total |
|---|---|---|---|
| Mean | 57.5 ± 4.0 | 70.5 ± 4.4 | 64.0 ± 7.7 |
| Sex: Female, Male(Participants) | 13vPnC (50 to 64 Years of Age) | 13vPnC (≥65 Years of Age) | Total |
|---|---|---|---|
| Female | 76 | 70 | 146 |
| Male | 58 | 64 | 122 |
The record gives a start of Oct 2007, a primary completion of Dec 2007 and a completion of Dec 2007. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2011, 3 years 11 months after primary completion. A results delay was requested in Jan 2009.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine